Skip to main
GMED

Globus Medical (GMED) Stock Forecast & Price Target

Globus Medical (GMED) Analyst Ratings

Based on 13 analyst ratings
Buy
Strong Buy 31%
Buy 46%
Hold 23%
Sell 0%
Strong Sell 0%

Bulls say

Globus Medical is a strong, growing company with a solid track record and impressive first quarter performance, indicating a positive outlook for the future. With a focus on recurring revenue and expanding their product offerings, as well as potential mergers and acquisitions, GMED is well positioned for continued growth in the medical device market. Furthermore, their strong leadership and board, along with a favorable analyst rating, solidify the company's positive outlook.

Bears say

Globus Medical is facing several potential risks, primarily in the form of increased competition from larger medical device companies and pricing pressure, which could disrupt its market share and negatively impact profit margins. Additionally, staffing shortages and macroeconomic factors may also pose challenges for the company. Despite potential growth opportunities through the adoption of its robotic technology, there is no guarantee that this will lead to sustained revenue and profit growth, and the success of the recent merger with Nuvasive remains uncertain. As such, the overall outlook for Globus Medical is negative, with limited potential for significant organic revenue and EPS growth in the coming years.

Globus Medical (GMED) has been analyzed by 13 analysts, with a consensus rating of Buy. 31% of analysts recommend a Strong Buy, 46% recommend Buy, 23% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Globus Medical and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Globus Medical (GMED) Forecast

Analysts have given Globus Medical (GMED) a Buy based on their latest research and market trends.

According to 13 analysts, Globus Medical (GMED) has a Buy consensus rating as of Aug 27, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $100, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $100, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Globus Medical (GMED)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.